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| INTRODUC TI ON
Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor has accumulated extensive efficacy and safety data from various meta-analyses of randomized controlled trials (RCTs), large RCTs, or noninterventional studies. 1 Its glycemic efficacy, reduced risk of hypoglycaemia, weight-neutral effect and favourable benefit-risk profile have made it an attractive treatment option for the management of patients with type 2 diabetes mellitus (T2DM) including those with renal impairment, heart failure, the elderly, or patients fasting during Ramadan. [1] [2] [3] However, there has been an interest in specific safety outcomes that may be associated with DPP-4 inhibitors in general [4] [5] [6] as well as with vildagliptin specifically. 1 Findings from a small clinical study reported that decreased DPP-4 activity may increase substance P or bradykinin concentrations, which can potentially increase the risk of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema. 7 Preclinical studies with cynomolgus monkeys reported vildagliptin-related skin lesions located on the distal extremities (including hands, feet, tips of ears, and tail) at high doses. 8 In-vitro studies showed suppression of human lymphocyte proliferation with vildagliptin, 9 which can potentially increase the risk of infections, this however, was not observed in in-vivo immunotoxicity studies. 10 Furthermore, two meta-analyses of RCTs in patients with type 2 diabetes mellitus also suggested an increased risk of all-cause infections (including nasophar-
yngitis, upper respiratory tract infection, and urinary tract infection)
with DPP-4 inhibitors. 11, 12 Rare cases of hepatic dysfunction (including hepatitis and elevated transaminases) were reported with vildagliptin use, which were however asymptomatic and nonprogressive. 3 In this context, the present noninterventional, postauthorization safety study was undertaken by the marketing authorization holder of vildagliptin as part of a commitment to the European Committee for Medicinal Products for Human Use (CHMP), 13 to assess whether vildagliptin is associated with an increased risk of angioedema, foot ulcers, skin lesions, adverse hepatic events, or serious infections compared with other noninsulin antidiabetic drugs (NIADs) in a real-world setting.
| MATERIAL S AND ME THODS

| Study design
The present multidatabase, population-based, analytical cohort study used data from five European electronic healthcare databases: Table S1 ). To focus on incident events (ie, first-time event after start of follow-up), patients with an outcome of interest recorded on or before the start of follow-up were excluded (eg, patients with a prior angioedema event excluded for the angioedema assessment).
| Statistical analysis
Demographics and other baseline characteristics were descriptively 
| Ethics and good clinical practice
| RE SULTS
Of the 738 054 patients included, 20 973 (2.8%) received vildagliptin at any time during the study, with an average follow-up time of 1.4 years, resulting in 28 330 PYs of cumulative current vildagliptin exposure. Tables S2 and S3 .
Patients on vildagliptin were younger, had a higher BMI, and shorter follow-up. The percentage of women was generally lower in the vildagliptin cohort (except for Denmark). Otherwise, baseline characteristics were comparable.
| Angioedema
No evidence was found for an increased risk of angioedema associated with vildagliptin compared with other NIADs, with adjusted
IRRs ranging from 0.87 to 3.71 and all 95% CIs crossing the null value 
| Foot ulcer
No evidence was identified for an increased risk of foot ulcer associated with use of vildagliptin compared with other NIADs, with adjusted IRRs close to 1 (range: 0.73-1.19) and all 95% CIs crossing 1 ( Figure 1 ). One subgroup analysis in CPRD suggestive of an increased risk was identified in the 18-39 age group (with a single case in the vildagliptin group) but with a corresponding adjusted P-value of 1.0.
| Skin lesion
No evidence for an increased risk was identified for vildagliptin compared with other NIADs for skin lesions, with adjusted IRRs below or close to 1 (range: 0.37-1.18) and all 95% CIs crossing 1 (Figure 1 ).
| Foot ulcer or skin lesions (composite)
No evidence for an increased risk was identified for vildagliptin compared with other NIADs for foot ulcers or skin lesions with adjusted IRRs below or close to 1 (range: 0.24-1.14) with 95% CIs crossing 1 ( Figure 1) . One subgroup analysis in men from IMS DA Germany was suggestive of an increased risk for vildagliptin with a lower bound of the 95% CI crossing 1, but a corresponding adjusted P-value of 1.0.
| Serious hepatic events
No evidence for an increased risk for serious hepatic events was iden- Due to zero cases identified in the vildagliptin group in the Swedish National Registers, no risk estimates were assessed for this database.
| ALT or AST > 3-times ULN and bilirubin > 2-times ULN (only assessed in CPRD GOLD)
The adjusted IRR for ALT or AST > 3-times ULN and bilirubin > 2-times ULN was not suggestive of an increased risk associated with vildagliptin compared to other NIADs (0.72; 95% CI: 0.42-1.25).
| ALT or AST > 10-times ULN (only assessed in CPRD GOLD)
The adjusted IRR for ALT or AST > 10-times ULN was 1.61 (95% CI:
0.51-5.08) and not suggestive of an increased relative risk associated with vildagliptin compared with other NIADs. One subgroup analysis in patients aged ≥65 years (based on three cases in the vildagliptin group) was suggestive of an increased risk (however, the corresponding adjusted P-value was 1.0).
| Any hepatic toxicity (composite of serious hepatic events or hepatic enzyme abnormalities [only assessed in CPRD GOLD])
The adjusted IRR for hepatic toxicity was 0.67 (95% CI: 0.40-1.13)
and not suggestive of an increased relative risk associated with vildagliptin compared with other NIADs.
| Serious infections
No evidence for an increased risk for serious infections was identi- 
| D ISCUSS I ON
This noninterventional, multidatabase, postmarketing safety study provides evidence that the use of vildagliptin is not associated with an increased risk of angioedema, foot ulcers, skin lesions, hepatic toxicity, and serious infections when compared to other NIADs under real-world conditions. Some subgroup analyses based on age and sex yielded risk ratios that are suggestive of an increased or decreased risk (ie, with 95% CIs not crossing 1). However, such analyses were generally based on very few cases in association with vildagliptin use, adjustment was generally done only for age and sex, and results for those estimates suggestive of an increased risk did not reach statistical significance based on the adjusted P-value. The most likely explanation for such results could be chance findings because of multiple testing.
No evidence of an increased risk of angioedema with vildagliptin exposure was observed. An earlier meta-analysis from phase III RCTs is in line with our results, reporting no association between vildagliptin use and angioedema. 14 No indication of an increased risk of foot ulcers and/or skin lesions was seen in patients exposed to vildagliptin. These results are consistent with a meta-analysis of 38 phase II and phase III clinical trials. The incidence of skin-related adverse events was low with vildagliptin, and similar to that of the comparators (OR = 1.10; 95% CI: 0.80-1.51; P = 0.70). 15 In a pooled analysis, similar frequencies of skin-related adverse events were seen with vildagliptin (12.6%) and comparators (14.4%). 16 In a retrospective cohort study, the incidence of diabetic foot ulcers was similar for vildagliptin in comparison with sulfonylurea (OR = 0.76; 95% CI: 0.57-1.03; P = 0.07). 
| Strengths and limitations
The broad inclusion/exclusion criteria of the current study done in Since the data were derived from electronic healthcare databases and the safety events were not further validated, there is a possibility of misclassification of events. In addition, as these analyses were only adjusted for age and sex, but not for other potential confounding variables (due to the limited number of patients with the outcomes of interest), residual confounding cannot be excluded.
| CON CLUS IONS
In conclusion, these safety analyses indicate that vildagliptin is not associated with an increased risk of angioedema, foot ulcer and/or skin lesions, hepatic toxicity, and serious infections when compared with other NIADs under real-world conditions. The current data complement earlier studies and meta-analyses of vildagliptin and add further evidence with respect to the positive safety profile of vildagliptin.
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